Gilles Lambert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/302306/publications.pdf

Version: 2024-02-01

50 papers	2,057 citations	279701 23 h-index	243529 44 g-index
51 all docs	51 docs citations	51 times ranked	2357 citing authors

#	Article	IF	Citations
1	The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Cardiovascular Research, 2022, 118, 2103-2111.	1.8	20
2	Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003489.	1.6	5
3	Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular Diabetology, 2022, 21, 21.	2.7	10
4	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. Current Atherosclerosis Reports, 2022, , 1.	2.0	2
5	Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATVBAHA122315499.	1.1	2
6	Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis, 2022, 349, 82-91.	0.4	26
7	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	1.1	5
8	PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 880-885.	1.1	6
9	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis, 2021, 326, 47-55.	0.4	18
10	Heart to heart with PCSK9. European Heart Journal, 2021, 42, 3091-3093.	1.0	4
11	PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Hyperglycemic Mice Increases the Risk of Hemorrhagic Transformation of Ischemic Stroke. Stroke, 2021, 52, e545-e547.	1.0	1
12	Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study. Frontiers in Genetics, 2021, 12, 728526.	1.1	3
13	Lipoprotein metabolism in familial hypercholesterolemia. Journal of Lipid Research, 2021, 62, 100062.	2.0	31
14	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©rosclÃ©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	0.7	9
15	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. International Journal of Molecular Sciences, 2021, 22, 13602.	1.8	10
16	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis, 2020, 293, 49-56.	0.4	21
17	A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. Journal of Lipid Research, 2020, 61, 1128-1139.	2.0	22
18	VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 819-829.	1.1	27

#	Article	IF	Citations
19	Lipoprotein(a) Cellular Uptake ExÂVivo and Hepatic Capture InÂVivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC Basic To Translational Science, 2020, 5, 549-557.	1.9	21
20	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic To Translational Science, 2019, 4, 425-427.	1.9	5
21	PCSK9 inhibition for autosomal recessive hypercholesterolemia. Atherosclerosis, 2019, 284, 209-211.	0.4	2
22	Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report. European Heart Journal - Case Reports, 2019, 3, ytz019.	0.3	2
23	Inhibiting PCSK9 â€" biology beyond LDL control. Nature Reviews Endocrinology, 2019, 15, 52-62.	4.3	96
24	A hemorrhagic transformation model of mechanical stroke therapy with acute hyperglycemia in mice. Journal of Comparative Neurology, 2018, 526, 1006-1016.	0.9	28
25	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 592-598.	1.1	77
26	Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. Journal of Lipid Research, 2018, 59, 892-900.	2.0	25
27	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	0.6	44
28	Stable Isotope Kinetic Study of ApoM (Apolipoprotein M). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 255-261.	1.1	14
29	Key aspects of PCSK9 inhibition beyond LDL lowering. Current Opinion in Lipidology, 2018, 29, 453-458.	1.2	10
30	PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. Clinical Science, 2018, 132, 1075-1083.	1.8	39
31	Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. Journal of Clinical Lipidology, 2017, 11, 289-293.	0.6	3
32	Plasma PCSK9 measurement by liquid chromatographyâ€"Tandem mass spectrometry and comparison with conventional ELISA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 24-29.	1.2	10
33	The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Clinical Science, 2017, 131, 261-268.	1.8	34
34	PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35.	2.0	99
35	PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis, 2016, 254, 249-253.	0.4	54
36	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	1.1	23

#	Article	IF	Citations
37	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) ExÂVivo. JACC Basic To Translational Science, 2016, 1, 419-427.	1.9	94
38	Characterization of the First PCSK9 Gain of Function Homozygote. Journal of the American College of Cardiology, 2015, 66, 2152-2154.	1.2	30
39	PCSK9 inhibitors. Swiss Medical Weekly, 2015, 145, w14094.	0.8	13
40	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831.	5.1	90
41	Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2042-2047.	1.1	48
42	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
43	Normalization of Low-Density Lipoprotein Receptor Expression inÂReceptor Defective Homozygous Familial Hypercholesterolemia byÂInhibition of PCSK9 With Alirocumab. Journal of the American College of Cardiology, 2014, 64, 2299-2300.	1.2	30
44	Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation. Stroke, 2014, 45, 3086-3088.	1.0	14
45	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	1.2	57
46	The PCSK9 decade. Journal of Lipid Research, 2012, 53, 2515-2524.	2.0	355
47	Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 2008, 196, 659-666.	0.4	81
48	PCSK9: a promising therapeutic target for dyslipidemias?. Trends in Endocrinology and Metabolism, 2006, 17, 79-81.	3.1	28
49	Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor. Endocrinology, 2006, 147, 4985-4995.	1.4	105
50	Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry, 2006, 281, 6211-6218.	1.6	260